WO2024241281 - MODIFIED VECTORS
National phase entry:
Publication Number
WO/2024/241281
Publication Date
28.11.2024
International Application No.
PCT/IB2024/055053
International Filing Date
24.05.2024
Title **
[English]
MODIFIED VECTORS
[French]
VECTEURS MODIFIÉS
Applicants **
CSL BEHRING L.L.C.
SEATTLE CHILDREN’S HOSPITAL D/B/A SEATTLE CHILDREN’S RESEARCH INSTITUTE
Inventors
AESCHIMANN, Florian
MONTELLESE, Christian
Priority Data
63/469,040
25.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3874 | |
| EPO | Filing, Examination, Granting | 40881 | |
| Japan | Filing, Examination, Granting | 3586 | |
| South Korea | Filing, Examination, Granting | 4718 | |
| USA | Filing, Examination, Granting | 15590 |
Total:
68,649
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This disclosure relates generally to viral vectors useful for gene therapy applications. In particular the disclosure relates to lentiviral vectors, especially lentiviral vectors comprising modified insulator sequences.[French]
La présente invention concerne de manière générale des vecteurs viraux utiles pour des applications de thérapie génique. En particulier, l'invention concerne des vecteurs lentiviraux, en particulier des vecteurs lentiviraux comprenant des séquences isolantes modifiées.